Trametinib Causes Reversible Cardiotoxicity in Almost One-Quarter of Exposed Adults With NF1 In the TRAIN trial, 23% of adults with NF1 taking trametinib developed cardiac dysfunction, although it was mostly moderate and reversible.

#Cancer therapy-related cardiac dysfunction (#CTRCD) appeared in 23% of neurofibromatosis type 1 (#NF1) patients receiving #Trametinib monotherapy in the phase 2 TRAIN trial.

Read more: https://bit.ly/4lSnxS2

#RareDisease #MedSky

Trametinib and Fimepinostat May Be More Potent Than Approved Agents for MPNSTs in NF1 In preclinical studies, trametinib and fimepinostat outperformed selumetinib and mirdametinib in inhibiting NF1-related MPNST growth.

#Trametinib and #Fimepinostat demonstrated potent antitumor activity in malignant peripheral nerve sheath tumor (#MPNST) cell lines derived from patients with neurofibromatosis type 1 (#NF1). Study in Cancers.

Learn more: https://bit.ly/3Ntn2kL

#RareDisease #MedSky #NeurofibromatosisType1

#Trametinib treatment results in the feedback activation of multiple #ReceptorTyrosineKinases (RTKs) and subsequent treatment with #Anlotinib effectively mitigates KRAS-mutant #NSCLC progression through the MEK/RTK-IGFBP2-RTK signaling loop.

#STTT #OpenAccess: doi.org/10.1038/s413...

#BRAF V600E–Mutant Diffuse Pulmonary #Langerhans Cell Histiocytosis Successfully Treated With #Dabrafenib Plus #Trametinib: A Case Report
onlinelibrary.wiley.com/doi/10.1002/...

Combination therapy extends lifespan in mice – BioNews Central A combination therapy of trametinib and rapamycin extends the lifespan of mice by about 30 percent, improves their health in old age by reducing chronic inflammation, and delays the onset of cancer. ...

A #CombinationTherapy of #trametinib and #rapamycin extends the #lifespan of mice by about 30 percent, improves their health in old age by reducing #ChronicInflammation, and delays the onset of #cancer.
#LifespanExtension #Healthspan

✨The Anti-Aging Power Duo, How Rapamycin & Trametinib Could Transform the Way We Age 💊⏳ Discover how two cutting-edge cancer drugs—Rapamycin and Trametinib—could revolutionize healthy aging and longevity. This breakthrough study reveals their combined potential to extend life and reduce ...

✨The Anti-Aging Power Duo, How Rapamycin & Trametinib Could Transform the Way We Age 💊⏳

#Longevity #AntiAging #Rapamycin #Trametinib #HealthyAging #LifeExtension #Geroprotector #Biohacking #AgingReversal #UltimateHealingSolutions
ultimatehealingsolutions.com/2025/05/30/%...

Hikma Pharmaceuticals Expands Portfolio with Novugen's Trametinib ANDA Acquisition Hikma Pharmaceuticals has successfully acquired Novugen's FDA-approved ANDA for trametinib, enhancing its portfolio in oncology treatments.

Hikma Pharmaceuticals Expands Portfolio with Novugen's Trametinib ANDA Acquisition #London #United_Kingdom #Hikma_Pharmaceuticals #Novugen #trametinib

@US_FDA approves #Futibatinib for FGFR2+ Advanced #CCA. It’s been a great 2 years for BTC survivors with addition of #durvalumab + gem/cis as well as #ivosidenib (IDH1) #infigratinib #pemigatinib (FGFR2 fusion) #dabrafenib #trametinib (BRAF V600E)

@ILCAnews @MacarullaTeresa
3 @US_FDA & EMA approved #CCA targeted rx #pemigatinib #ivosidenib #dabrafenib #trametinib Unfortunately #NGS which identifies targeted rx underutilized & often not reimbursed. #NGS endorsed by @myESMO for all #CCA #ILCA22 @CCA_Alliance @curecc